Sánchez Rivas, Edgardo J. https://orcid.org/0000-0002-6456-3676
Sadler, Fredrik
Safdari, Mohammadamin
Patel, Nishaben M. https://orcid.org/0000-0003-4724-5710
Ritt, Michael
Ma, Ning https://orcid.org/0000-0003-4653-7797
Branciamore, Sergio https://orcid.org/0000-0002-2556-8765
Vaidehi, Nagarajan https://orcid.org/0000-0001-8100-8132
Sivaramakrishnan, Sivaraj https://orcid.org/0000-0002-9541-6994
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (R35-GM126940)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (R35-GM156498)
U.S. Department of Health & Human Services | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases (T32-AR007612)
U.S. Department of Health & Human Services | NIH | U.S. National Library of Medicine (R01-LM013876)
Article History
Received: 15 May 2025
Accepted: 21 April 2026
First Online: 6 May 2026
Competing interests
: F.S. and S.S. are co-founders of Oxbow Therapeutics. S.S. is a co-inventor on US patent US12098184B2. All other authors declare no competing interests.